Abstract
Chimeric or hybrid herpes simplex virus type 1/adeno-associated virus amplicon vectors combine the large transgene capacity of HSV-1 with the potential for site-specific genomic integration and stable transgene expression of AAV. These chimeric vectors have been demonstrated to support transgene expression for significantly longer periods than standard HSV-1 amplicons. Moreover, HSV/AAV hybrid vectors can mediate integration at the AAVS1 preintegration site on human chromosome 19 at a relatively high rate, although random integration has also been observed. One major remaining hurdle of HSV/AAV hybrid vectors is the low packaging efficiency and titers when AAV rep sequences are included in the amplicon vector. In the conditions prevalent during the replication/packaging of HSV/AAV hybrid amplicons into HSV-1 virions, in particular the presence of HSV-1 replication factors and AAV Rep protein, at least three different viral origins of DNA replication are active: the HSV-1 ori, the AAV inverted terminal repeats (ITRs), and the p5 promoter/ori driving expression of the AAV rep gene. A detailed understanding of the properties of these origins of DNA replication and the molecular mechanisms of interactions between them, may allow designing novel hybrid vectors that allow the efficient and precise integration of large transgenes in the human genome.
Keywords: HSV/AAV hybrid amplicon, site-specific integration, virus-virus interaction, replication compartment
Current Gene Therapy
Title: Chimeric Herpes Simplex Virus/Adeno-Associated Virus Amplicon Vectors
Volume: 6 Issue: 3
Author(s): Daniel L. Glauser, Mathias Ackermann, Okay Saydam and Cornel Fraefel
Affiliation:
Keywords: HSV/AAV hybrid amplicon, site-specific integration, virus-virus interaction, replication compartment
Abstract: Chimeric or hybrid herpes simplex virus type 1/adeno-associated virus amplicon vectors combine the large transgene capacity of HSV-1 with the potential for site-specific genomic integration and stable transgene expression of AAV. These chimeric vectors have been demonstrated to support transgene expression for significantly longer periods than standard HSV-1 amplicons. Moreover, HSV/AAV hybrid vectors can mediate integration at the AAVS1 preintegration site on human chromosome 19 at a relatively high rate, although random integration has also been observed. One major remaining hurdle of HSV/AAV hybrid vectors is the low packaging efficiency and titers when AAV rep sequences are included in the amplicon vector. In the conditions prevalent during the replication/packaging of HSV/AAV hybrid amplicons into HSV-1 virions, in particular the presence of HSV-1 replication factors and AAV Rep protein, at least three different viral origins of DNA replication are active: the HSV-1 ori, the AAV inverted terminal repeats (ITRs), and the p5 promoter/ori driving expression of the AAV rep gene. A detailed understanding of the properties of these origins of DNA replication and the molecular mechanisms of interactions between them, may allow designing novel hybrid vectors that allow the efficient and precise integration of large transgenes in the human genome.
Export Options
About this article
Cite this article as:
Glauser L. Daniel, Ackermann Mathias, Saydam Okay and Fraefel Cornel, Chimeric Herpes Simplex Virus/Adeno-Associated Virus Amplicon Vectors, Current Gene Therapy 2006; 6 (3) . https://dx.doi.org/10.2174/156652306777592090
DOI https://dx.doi.org/10.2174/156652306777592090 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Biological Role of mTOR in the Pathogenesis of Solid Tumors: An Overview
Current Enzyme Inhibition Effects of LPA and S1P on the Nervous System and Implications for Their Involvement in Disease
Current Drug Targets Targeting the BRCA1/2 Tumor Suppressors
Current Drug Targets Stimuli-Responsive Nanocarriers for Drug Delivery to the Central Nervous System
Current Nanoscience Identification and Analysis of RNA Editing Events in Ovarian Serous Cystadenoma Using RNA-seq Data
Current Gene Therapy Finding Recurrent Copy Number Alteration Regions: A Review of Methods
Current Bioinformatics Recent Development in the Fabrication of Collagen Scaffolds for Tissue Engineering Applications: A Review
Current Pharmaceutical Biotechnology HSP60 as a Drug Target
Current Pharmaceutical Design Cannabinoids as Neuroprotective Agents in Traumatic Brain Injury
Current Pharmaceutical Design Drug Design Studies of the Novel Antitumor Targets Carbonic Anhydrase IX and XII
Current Medicinal Chemistry Aptamers in Targeted Nanotherapy
Current Topics in Medicinal Chemistry Early Genetic Changes Involved in Low-Grade Astrocytic Tumor Development
Current Molecular Medicine Seizures and Anticonvulsants in Brain Tumours: Frequency, Mechanisms and Anti-Epileptic Management
Current Pharmaceutical Design Endogenous Angiogenesis Inhibitors as Therapeutic Agents: Historical Perspective and Future Direction
Recent Patents on Anti-Cancer Drug Discovery Epigenetic Regulation of Cytochrome P450 Enzymes and Clinical Implication
Current Drug Metabolism <i>DBX2</i> Promotes Glioblastoma Cell Proliferation by Regulating <i>REST</i> Expression
Current Pharmaceutical Biotechnology Relevance of the Deletion Polymorphisms of the Glutathione S-Transferases GSTT1 and GSTM1 in Pharmacology and Toxicology
Current Drug Metabolism Cause and Consequences of Genetic and Epigenetic Alterations in Human Cancer
Current Genomics The Urokinase Receptor as a Potential Target in Cancer Therapy
Current Pharmaceutical Design Role of PARP Inhibitors in Cancer Biology and Therapy
Current Medicinal Chemistry